To explore the pathways involved in the effects of EVs isolated from SSc patients on HUVECs and smooth muscle cells, which is an aspect not yet investigated, we conducted experiments by using inhibitors targeting Akt/PI3K, AMPK, MEK1/2/ERK1/2, PKA, and CAMKII. This evidence concerns the gene MAP2K1 and systemic sclerosis.